Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 studyAnthony R. Mato, Michael Wang, Alvaro J. Alencar et al.|The Lancet|2021Cited by 456
Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic LeukemiaAnthony R. Mato, Wojciech Jurczak, Jennifer A. Woyach et al.|New England Journal of Medicine|2023Cited by 213
The Impact of EBV Status on Characteristics and Outcomes of Posttransplantation Lymphoproliferative DisorderMarlise R. Luskin, Ran Reshef, Daniel S. Heil et al.|American Journal of Transplantation|2015Cited by 174
Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell LymphomaMichael Wang, Nirav N. Shah, Wojciech Jurczak et al.|Journal of Clinical Oncology|2023Cited by 106
Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1/2 BRUIN studyWilliam G. Wierda, Paolo Ghia, Nirav N. Shah et al.|The Lancet Haematology|2024Cited by 37